PD-1 blockade, which reinvigorates the tumor-reactive CD8+ T cells by removing the inhibition induced by the interaction of PD-1 and PD-L1, has achieved high success in mediating complete, durable responses in patients with advanced or conventional therapy-resistant cancers; however, the successes are unfortunately limited to a minority of patients1–3. This evidence concerns the gene CD274 and cancer.